MENU
+Compare
ERAS
Stock ticker: NASDAQ
AS OF
Nov 24, 04:59 PM (EDT)
Price
$2.88
Change
-$0.04 (-1.37%)
Capitalization
817.09M

ERAS Erasca Forecast, Technical & Fundamental Analysis

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers... Show more

ERAS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ERAS with price predictions
Nov 21, 2025

ERAS's RSI Oscillator climbs into overbought territory

The RSI Indicator for ERAS moved into overbought territory on November 21, 2025. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ERAS broke above its upper Bollinger Band on November 17, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ERAS entered a downward trend on November 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 12, 2025. You may want to consider a long position or call options on ERAS as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ERAS just turned positive on November 13, 2025. Looking at past instances where ERAS's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in of 216 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.349) is normal, around the industry mean (27.249). P/E Ratio (0.000) is within average values for comparable stocks, (51.596). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.881). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (320.418).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ERAS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ERAS is expected to report earnings to fall 4.00% to -10 cents per share on March 19

Erasca ERAS Stock Earnings Reports
Q4'25
Est.
$-0.11
Q3'25
Missed
by $0.01
Q2'25
Est.
$-0.12
Q1'25
Beat
by $0.02
Q4'24
Beat
by $0.02
The last earnings report on November 12 showed earnings per share of -10 cents, missing the estimate of -10 cents. With 1.90M shares outstanding, the current market capitalization sits at 817.09M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
3115 Merryfield Row
Phone
+1 858 465-6511
Employees
126
Web
https://www.erasca.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSCSX25.340.34
+1.36%
Homestead Small Company Stock
ACFSX80.19N/A
N/A
American Century Focused Dynamic Gr I
LGORX25.87N/A
N/A
Lord Abbett Growth Opportunities R3
WSMGX21.41N/A
N/A
Wilshire Small Company Growth Instl
FKUQX25.98N/A
N/A
Franklin Utilities A

ERAS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with OCUL. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+5.04%
OCUL - ERAS
53%
Loosely correlated
+4.44%
XNCR - ERAS
52%
Loosely correlated
+1.89%
EYPT - ERAS
48%
Loosely correlated
+0.29%
RVMD - ERAS
47%
Loosely correlated
+1.42%
IMTX - ERAS
47%
Loosely correlated
+0.99%
More